Search Results - "Seong, C.M."

Long-term efficacy of sequential vincristine, adriamycin, and dexamethasone (VAD) and bortezomib, thalidomide, and dexamethasone (VTD) as induction chemotherapy followed by high-dose melphalan with autologous stem cell transplantation (auto-SCT) and bortezomib consolidation: a follow-up study of KMM51 by Shin, J, Koh, Y, Kim, H.J, Yoon, S.-S, Lee, D.S, Sohn, S.K, Eom, H.S, Lee, J.L, Chung, J.S, Kim, K, Suh, C, Won, J.H, Kim, J.S, Park, J.S, Kang, H.J, Seong, C.M, Kim, C.S, Lee, S.J, Lee, J.H

Get full text

O-019 Head-to-head comparison of 5-azacitidine versus decitabine for the treatment of myelodysplastic syndrome by Kim, I, Lee, Y.G, Yoon, S.S, Park, S, Cheong, J.W, Min, Y.H, Bang, S.M, Kim, C.S, Park, Y, Mun, Y.C, Seong, C.M, Park, J, Lee, J.H, Lee, H.G, Kim, Y.K, Kim, H.J

Get full text

Prognostic significance of triple-negative phenotype in breast cancer by Lee, K.E, Choi, M.Y, Chang, H.J, Sung, S.H, Moon, B.I, Choi, H.Y, Nam, E.M, Mun, Y.C, Seong, C.M, Lee, S.N

Get full text

Interim Anaiysis of Intention To Treat Analysis, “Multicenter AML-2000 Trial” Based on Cytogenetics Risk Factors by Mun, Yeung-Chul, Lee, S.M., Bang, S.M., Park, S.H., Cho, E.K., Lee, J.H., Jo, D.Y., Kim, S.Y., Kim, I.H., Yoon, S.S., Park, S.Y., Kim, B.K., Min, Y.J., Seo, J.J., Ghim, Thad, Lee, M.H., Kim, C.S., Joo, Y.D., Chung, S.Y., Oh, D.Y., Ahn, J.S., Zang, D.Y., Lee, K.H., Kim, M.K., Hyun, M.S., Song, H.S., Kim, H.S., Kwon, H.C., Kim, H.J., Park, K.T., Bae, S.H., Ryoo, H.M., Ahn, M.J., Yoon, H.J., Kim, B.S., Park, Y.H., Seong, C.M.

“…The result of cytogenetics is one of the most important prognostic factors on the prognosis of AML. HDAC, auto PBPCT and allogeneic BMT after 1 or 2 times of…”
Get full text

Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics by Nigam, M, Seong, C M, Qian, Y, Hamilton, A D, Sebti, S M

“…The ras oncogene product p21ras requires farnesylation and subsequent plasma membrane association for its transforming activity. This key post-translational…”
Get full text

Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase by Qian, Y, Blaskovich, M A, Saleem, M, Seong, C M, Wathen, S P, Hamilton, A D, Sebti, S M

“…Cysteine farnesylation of the ras oncogene product, p21ras, on its carboxyl-terminal CA1A2X box (C = cysteine, A = aliphatic, and X = methionine or serine) is…”
Get full text